You have established cardiovascular disease and want proven heart protection data Your private insurance covers it You prefer an approved medication with 7+ years of safety tracking You have responded well to GLP-1 medications before You are in a province where your doctor can easily prescribe it You want the highest weight loss efficacy available in any injectable You have plateaued on single or dual-agonist medications You are comfortable with Phase 3 trial-level data rather than long-term post-market data You prefer accessible pricing without insurance hassles You value domestic Canadian shipping and CAD pricing Both options share absolute contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy or planned pregnancy within 2-3 months, and history of severe allergic reaction to medication components
Images taken at 100x, with zoom applied
87 % of treated participants achieved 5 % weight-loss [Medical Xpress]
1 Beyond its well-known implications, such as insulin resistance and obesity , PCOS is a leading cause of infertility due to irregular menstrual cycles and hormonal imbalances
Meanwhile, Latin America accounts for 8.2% of global market share, with Brazil, Mexico, and Colombia serving as primary growth markets where diabetes prevalence continues accelerating amid expanding healthcare infrastructure
